

# Bryan R Kestenbaum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9479087/publications.pdf>

Version: 2024-02-01

104  
papers

4,449  
citations

101543

36  
h-index

114465

63  
g-index

104  
all docs

104  
docs citations

104  
times ranked

7530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney Tubulointerstitial Fibrosis and Tubular Secretion. American Journal of Kidney Diseases, 2022, 79, 709-716.	1.9	13
2	Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis. American Journal of Clinical Nutrition, 2022, 115, 914-924.	4.7	5
3	Validation of the 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 ratio as a biomarker of 25-hydroxyvitamin D3 clearance. Journal of Steroid Biochemistry and Molecular Biology, 2022, 217, 106047.	2.5	6
4	Kidney Tubular Injury Biomarkers and Secretary Function in Acute Decompensated Heart Failure. Kidney Medicine, 2022, 4, 100418.	2.0	0
5	Association of Clonal Hematopoiesis of Indeterminate Potential with Worse Kidney Function and Anemia in Two Cohorts of Patients with Advanced Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2022, 33, 985-995.	6.1	45
6	Association of Proximal Tubular Secretary Clearance with Long-Term Decline in Cognitive Function. Journal of the American Society of Nephrology: JASN, 2022, 33, 1391-1401.	6.1	5
7	Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3866-e3876.	3.6	3
8	Comparison of host endothelial, epithelial and inflammatory response in ICU patients with and without COVID-19: a prospective observational cohort study. Critical Care, 2021, 25, 148.	5.8	26
9	The Multi-Ethnic Study of Atherosclerosis individual response to vitamin D trial: Building a randomized clinical trial into an observational cohort study. Contemporary Clinical Trials, 2021, 103, 106318.	1.8	1
10	Assessment of kidney proximal tubular secretion in critical illness. JCI Insight, 2021, 6, .	5.0	9
11	Relationship Between Chronic Kidney Disease, Glucose Homeostasis, and Plasma Osteocalcin Carboxylation and Fragmentation. , 2021, 31, 248-256.		5
12	An Introduction to Qualitative Inquiry. Journal of the American Society of Nephrology: JASN, 2021, 32, 1275-1278.	6.1	4
13	Bone mineral density and long-term progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2021, 335, 126-134.	0.8	12
14	Kidney Function and Subclinical Arrhythmias: The Multi-Ethnic Study of Atherosclerosis. Kidney Medicine, 2021, 3, 1102-1105.	2.0	0
15	Association Between Kidney Clearance of Secretary Solutes and Cardiovascular Events: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2021, 78, 226-235.e1.	1.9	7
16	Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis. Kidney International, 2021, 100, 672-683.	5.2	21
17	Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 188-198.	6.1	18
18	Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 1916-1923.	0.7	8

#	ARTICLE	IF	CITATIONS
19	Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1144-e1151.	3.6	8
20	Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. <i>Kidney360</i> , 2020, 1, 1206-1216.	2.1	10
21	Race, Ancestry, and Vitamin D Metabolism: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4337-e4350.	3.6	38
22	Fibroblast Growth Factor 23 and Long-Term Cardiac Function. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e011925.	2.6	21
23	Serum Aldosterone Concentration, Blood Pressure, and Coronary Artery Calcium. <i>Hypertension</i> , 2020, 76, 113-120.	2.7	42
24	Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 616-623.	0.7	5
25	Association of Tubular Solute Clearance with Symptom Burden in Incident Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 530-538.	4.5	4
26	Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. <i>Kidney International Reports</i> , 2019, 4, 1598-1607.	0.8	19
27	Soluble ST2 and Galectin-3 and Progression of CKD. <i>Kidney International Reports</i> , 2019, 4, 103-111.	0.8	41
28	Comparative Safety of Phosphate Binders Without Proven Efficacy—How Did We Get Here?. <i>JAMA Internal Medicine</i> , 2019, 179, 749.	5.1	4
29	Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2019, 285, 79-86.	0.8	26
30	Urinary Concentration Ability: Time to Bring the Tubules to the Table. <i>American Journal of Kidney Diseases</i> , 2019, 73, 583-584.	1.9	1
31	A Prediction Model for Severe AKI in Critically Ill Adults That Incorporates Clinical and Biomarker Data. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 506-514.	4.5	25
32	The association of glycosylated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 296-301.	2.3	12
33	Comparative Effects of Cholecalciferol and Calcitriol on Circulating Markers of CKD Mineral Bone Disorder. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 927-928.	4.5	7
34	Transethnic Evaluation Identifies Low-Frequency Loci Associated With 25-Hydroxyvitamin D Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1380-1392.	3.6	33
35	Stuck in a Bind With Phosphate Binders. <i>American Journal of Kidney Diseases</i> , 2018, 71, 254-256.	1.9	0
36	Commentary on Lessons from CKD-Related Genetic Association Studies—Moving Forward. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 153-154.	4.5	2

#	ARTICLE	IF	CITATIONS
37	Commentary on Treatment of Severe Hyponatremia. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 650-651.	4.5	2
38	Association of cardiovascular disease risk factors with coronary artery calcium volume versus density. Heart, 2018, 104, 135-143.	2.9	22
39	Association of Soluble TNFR-1 Concentrations with Long-Term Decline in Kidney Function: The Multi-Ethnic Study of Atherosclerosis. Journal of the American Society of Nephrology: JASN, 2018, 29, 2713-2721.	6.1	46
40	Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. Journal of the American Society of Nephrology: JASN, 2018, 29, 2583-2592.	6.1	35
41	Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes. American Journal of Nephrology, 2018, 48, 56-64.	3.1	4
42	GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2018, 72, 519-528.	1.9	82
43	Chronic kidney disease attenuates the plasma metabolome response to insulin. JCI Insight, 2018, 3, .	5.0	21
44	Echocardiographic Measures and Estimated GFR Decline Among African Americans: The Jackson Heart Study. American Journal of Kidney Diseases, 2017, 70, 199-206.	1.9	17
45	Commentary on Symptom Management of the Patient with CKD: The Role of Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 694-695.	4.5	1
46	Growth Differentiation Factorâ€“15 and Risk of CKD Progression. Journal of the American Society of Nephrology: JASN, 2017, 28, 2233-2240.	6.1	127
47	Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E175-E182.	3.5	5
48	Relation of Serum Vitamin D to Risk of Mitral Annular and Aortic Valve Calcium (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 Td (	1.6	7
49	Associations of Vitamin Dâ€“Binding Globulin and Bioavailable Vitamin D Concentrations With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3075-3084.	3.6	30
50	Serum Phosphate and Retinal Microvascular Changes: The Multi-Ethnic Study of Atherosclerosis and the Beaver Dam Eye Study. Ophthalmic Epidemiology, 2017, 24, 371-380.	1.7	8
51	Association of Muscle Endurance, Fatigability, and Strength With Functional Limitation and Mortality in the Health Aging and Body Composition Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 284-291.	3.6	60
52	Genetic Variants Associated with Circulating Parathyroid Hormone. Journal of the American Society of Nephrology: JASN, 2017, 28, 1553-1565.	6.1	52
53	Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease. JAMA Cardiology, 2017, 2, 314.	6.1	115
54	The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension. Annals of Internal Medicine, 2017, 167, 630.	3.9	127

#	ARTICLE	IF	CITATIONS
55	Kidney function is associated with an altered protein composition of high-density lipoprotein. <i>Kidney International</i> , 2017, 92, 1526-1535.	5.2	37
56	Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis. <i>American Journal of Human Genetics</i> , 2017, 101, 227-238.	6.2	112
57	Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients. <i>EBioMedicine</i> , 2017, 26, 68-77.	6.1	103
58	Commentary on Biomarkers for Early Detection and Prognosis of AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 174-175.	4.5	4
59	Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1239-1246.	6.1	26
60	Con: Phosphate binders in chronic kidney disease Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv406.	0.7	6
61	Vitamin D and Risk of Neuroimaging Abnormalities. <i>PLoS ONE</i> , 2016, 11, e0154896.	2.5	12
62	Potassium Measures and Their Associations with Glucose and Diabetes Risk: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>PLoS ONE</i> , 2016, 11, e0157252.	2.5	14
63	Fibroblast Growth Factor 23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 270-276.	2.6	24
64	Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. <i>BMC Nephrology</i> , 2016, 17, 187.	1.8	20
65	Vitamin D and Memory Decline: Two Population-Based Prospective Studies. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1099-1108.	2.6	41
66	Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1003-1009.	2.4	63
67	Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. <i>Atherosclerosis</i> , 2016, 248, 224-229.	0.8	14
68	Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS). <i>American Journal of Kidney Diseases</i> , 2016, 68, 229-239.	1.9	66
69	Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2057-2064.	0.7	10
70	Development and Validation of a Sudden Cardiac Death Prediction Model for the General Population. <i>Circulation</i> , 2016, 134, 806-816.	1.6	97
71	Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1384-1391.	4.5	32
72	Commentary on Pharmacotherapy of Hypertension in Patients on Chronic Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2076-2077.	4.5	0

#	ARTICLE	IF	CITATIONS
73	Introducing the Evidence-Based Nephrology Series. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2061-2061.	4.5	0
74	Parathyroid Hormone and the Use of Diuretics and Calcium-Channel Blockers: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1137-1145.	2.8	21
75	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 188-189.	0.7	1
76	Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease. , 2016, 26, 93-102.		27
77	Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients. <i>PLoS ONE</i> , 2016, 11, e0161074.	2.5	48
78	Plasma vitamin D is associated with fasting insulin and homeostatic model assessment of insulin resistance in young adult males, but not females, of the Jerusalem Perinatal Study. <i>Public Health Nutrition</i> , 2015, 18, 1324-1331.	2.2	14
79	Fibroblast Growth Factor 23 and Sudden Versus Non-sudden Cardiac Death: The Cardiovascular Health Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 40-46.	1.9	18
80	Urinary uromodulin, kidney function, and cardiovascular disease in elderly adults. <i>Kidney International</i> , 2015, 88, 1126-1134.	5.2	79
81	Creatinine Clearance, Walking Speed, and Muscle Atrophy: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 737-747.	1.9	51
82	NT-ProBNP and Troponin T and Risk of Rapid Kidney Function Decline and Incident CKD in Elderly Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 205-214.	4.5	46
83	Genetic and Environmental Factors Are Associated with Serum 25-Hydroxyvitamin D Concentrations in Older African Americans. <i>Journal of Nutrition</i> , 2015, 145, 799-805.	2.9	23
84	Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1024-1031.	2.3	22
85	Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2099-2105.	0.7	29
86	Self-Rated Health and Adverse Events in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 2044-2051.	4.5	28
87	Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population. <i>Circulation: Heart Failure</i> , 2014, 7, 409-417.	3.9	130
88	Estimated GFR and Circulating 24,25-Dihydroxyvitamin D <sub>3</sub> Concentration: A Participant-Level Analysis of 5 Cohort Studies and Clinical Trials. <i>American Journal of Kidney Diseases</i> , 2014, 64, 187-197.	1.9	62
89	Estimation of 24-Hour Urine Phosphate Excretion From Spot Urine Collection: Development of a Predictive Equation. , 2014, 24, 194-199.		15
90	Association of 25-Hydroxyvitamin D and Parathyroid Hormone With Incident Hypertension. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1214-1222.	2.8	73

#	ARTICLE	IF	CITATIONS
91	Vitamin D and the risk of dementia and Alzheimer disease. <i>Neurology</i> , 2014, 83, 920-928.	1.1	439
92	Low Serum Bicarbonate and Kidney Function Decline: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>American Journal of Kidney Diseases</i> , 2014, 64, 534-541.	1.9	82
93	Fibroblast Growth Factor-23 and Incident Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 298-307.	1.6	123
94	Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals. <i>Journal of the American College of Cardiology</i> , 2012, 60, 200-207.	2.8	291
95	Cystatin C and Albuminuria as Risk Factors for Development of CKD Stage 3: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>American Journal of Kidney Diseases</i> , 2011, 57, 832-840.	1.9	28
96	Common Genetic Variants Associate with Serum Phosphorus Concentration. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1223-1232.	6.1	123
97	Incidence and progression of coronary calcification in chronic kidney disease: the Multi-Ethnic Study of Atherosclerosis. <i>Kidney International</i> , 2009, 76, 991-998.	5.2	91
98	Differences in Kidney Function and Incident Hypertension: The Multi-Ethnic Study of Atherosclerosis. <i>Annals of Internal Medicine</i> , 2008, 148, 501.	3.9	111
99	Why Choose Serum Cystatin C Levels over Serum Creatinine Levels as a Serologic Marker of Kidney Function?. <i>Annals of Internal Medicine</i> , 2008, 149, 284.	3.9	17
100	Kidney Function, Electrocardiographic Findings, and Cardiovascular Events among Older Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 501-508.	4.5	44
101	PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphate Metabolism in the Setting of Chronic Kidney Disease: Significance and Recommendations for Treatment. <i>Seminars in Dialysis</i> , 2007, 20, 286-294.	1.3	45
102	Survival following parathyroidectomy among United States dialysis patients. <i>Kidney International</i> , 2004, 66, 2010-2016.	5.2	212
103	Cardiovascular and thromboembolic events following hypertensive pregnancy. <i>American Journal of Kidney Diseases</i> , 2003, 42, 982-989.	1.9	134
104	Calcium channel blocker use and mortality among patients with end-stage renal disease. <i>Kidney International</i> , 2002, 61, 2157-2164.	5.2	94